News > Novavax awaits FDA decision on whether its next COVID shot can be offered in US

Novavax awaits FDA decision on whether its next COVID shot can be offered in US

Novavax's updated vaccine targets a variant called JN.1, which is in line with EU recommendations. The EU's regulator told vaccine makers last month to update their vaccines for that variant because they would likely be effective against its descendant lineages. The US FDA has not yet decided on the makeup of the next round of COVID vaccines and a JN.1 subvariant known as KP.2 has become dominant in the US over the past month.